Research spanning more than 20 years has led the UPV/EHU's Neurochemistry and Neurodegeneration group under Dr. Rafael ...

Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid ...

Research highlights the therapeutic potential of targeting cannabinoid receptors to counter memory impairment in early ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular ...

PhD In summary our results support the concept that cholinergic transmission is involved in the pathogenesis of OSA in Alzheimer disease, suggesting a possible target for pharmacologic intervention.